Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 1 · 50%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 50%Moderate 0 · 0%High 0 · 0%

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

Bamlanivimab/etesevimab may leads to lower mortality by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.05 [0, 0.81]
1 study · 1035 participants
Low

Mortality by day 60 ‐ not reported · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found